- Investing Ideas
- Japanese Pharmaceuticals & Biotech Too Big To Fail
Japanese Pharmaceuticals & Biotech Too Big To Fail
Results
5
Large established companies which pay a dividend.
5 companies
Astellas Pharma
Market Cap: JP¥3.8t
Engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally.
4503
JP¥2,138.50
7D
0.05%
1Y
47.3%
Shionogi
Market Cap: JP¥2.4t
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally.
4507
JP¥2,841.00
7D
0.2%
1Y
12.9%
Kyowa Kirin
Market Cap: JP¥1.4t
Engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally.
4151
JP¥2,637.50
7D
-1.4%
1Y
4.0%
Ono Pharmaceutical
Market Cap: JP¥1.1t
Produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.
4528
JP¥2,346.50
7D
-4.2%
1Y
44.4%
Santen Pharmaceutical
Market Cap: JP¥675.9b
Engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally.
4536
JP¥2,088.50
7D
-3.8%
1Y
23.3%